Although strategies targeting CD25 (like the neutralizing monoclonal antibody daclizumab and the recombinant interleukin 2/diphtheria toxin conjugate Ontak) showed transient depletion of peripheral Tregs and increased activity of CD8+ T cells, these approaches only result in a modest clinical benefit in cancer patients (83, 84). Here, CD8A is linked to cancer.